CStone Pharmaceuticals (2616) Stock Statistics & Valuation Metrics

CStone Pharmaceuticals has a market cap or net worth of HK$7.77B. The enterprise value is HK$5.77B.

CStone Pharmaceuticals has 1,596,330,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

CStone Pharmaceuticals’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -41.59%.

The current PE Ratio of CStone Pharmaceuticals is ―. CStone Pharmaceuticals’s PEG ratio is -0.05.

In the last 12 months, CStone Pharmaceuticals had revenue of 269.58M and earned -437.00M in profits. Earnings per share was -0.31.

In the last 12 months, operating cash flow was -277.60M and capital expenditures 4.00, giving a free cash flow of -277.60M billion.

CStone Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CStone Pharmaceuticals upcoming earnings date is Apr 1, 2027, TBA (Confirmed).

CStone Pharmaceuticals as a current ratio of 2.18, with Debt / Equity ratio of 27.64%

In the past 12 months, CStone Pharmaceuticals has paid 13.06M in taxes.

CStone Pharmaceuticals EV to EBITDA ratio is -16.58, with an EV/FCF ratio of -18.82.

CStone Pharmaceuticals has HK$1.56B in cash and marketable securities with HK$357.17M in debt, giving a net cash position of HK$1.20B billion.

Gross margin is 55.49%, with operating margin of -160.48%, and net profit margin of -162.10%.

The average price target for CStone Pharmaceuticals is HK$9.65, which is 11.43% higher than the current price. The consensus rating is Moderate Buy